Is cer a good long term investment

**Cere Network (CERE) does not appear to be a strong candidate for a good long-term investment**, based on the company's financial performance, recent news, and market sentiment. 1. **Financial Performance**: Cere Network has reported a net loss of $4.2 million for the fiscal quarter ending August 31, 2024, with a diluted EPS of $-0.03. The company's revenue growth rate is not available, which makes it difficult to assess the company's financial health. 2. **Recent News and Developments**: The company has faced significant challenges, including a failed Phase 2/3 trial for Rett syndrome and questionable efficacy and safety issues in Alzheimer's data. These setbacks could impact the company's future prospects. 3. **Market Sentiment**: The sentiment among analysts is cautious, with a recent downgrade due to poor clinical results, overvaluation, and high operational and financial risks. This sentiment could persist and affect the stock's long-term performance. 4. **Strategic Positioning**: Cere Network is developing engineered T cell immunotherapies, which could have long-term growth potential if successful. However, the company's focus on drug development and the risks associated with it could impact its financial performance in the short to medium term. 5. **Dividend Yield**: The dividend yield for Cere Network is currently not available, which makes it difficult to assess the immediate returns on investment through dividends. The lack of a dividend yield could be a deterrent for income-focused long-term investors. In conclusion, while Cere Network has made strides in developing engineered T cell immunotherapies, the negative financial performance, recent setbacks in drug trials, and cautious market sentiment suggest that CERE may not be an attractive long-term investment at this time. Investors should closely monitor the company's financial performance, market developments, and strategic progress to ensure they align with their investment goals.